Implantable sensor devices, systems, and methods
Disclosed herein are devices, systems, and methods for a continuous analyte sensor, such as a continuous glucose sensor. In certain embodiments disclosed herein, various in vivo properties of the sensor's surroundings can be measured. In some embodiments, the measured properties can be used to identify a physiological response or condition in the body. This information can then be used by a patient, doctor, or system to respond appropriately to the identified condition.
1. A method performed using a continuous glucose sensor, the method comprising:
receiving sensor data generated by a continuous glucose sensor, wherein the sensor data is indicative of a concentration of glucose in a user;
identifying, using a processor module, a post-implantation loss of sensitivity of the continuous glucose sensor, wherein identifying the post-implantation loss of sensitivity comprises:
measuring a first impedance associated with the continuous glucose sensor at a first time point;
measuring a second impedance associated with the continuous glucose sensor at a second time point, wherein the first time point is different than the second time point; and
determining an occurrence of the post-implantation loss of sensitivity by comparing the first impedance measurement with the second impedance measurement;
deactivating the continuous glucose sensor responsive to the determination of the occurrence of the post-implantation loss of sensitivity event;
based on the comparing of the first impedance measurement and the second impedance measurement, determining that the post-implantation loss of sensitivity event is temporary; and
after the continuous glucose sensor is deactivated, reactivating the continuous glucose sensor.
2. The method of claim 1 , wherein the sensor data comprises data indicative of a signal response to at least one event selected from the group consisting of a signal response to cessation of blood flow to a site surrounding sensor implantation, a signal response to reduction of blood flow to a site surrounding sensor implantation, and a signal response to a vasospastic event.
3. The method of claim 1 , wherein identifying the post-implantation loss of sensitivity further comprises:
deactivating the continuous glucose sensor for a time period, whereby a product from a catalyzed reaction of glucose and oxygen accumulates over the time period;
activating the continuous glucose sensor and measuring a signal value of the continuous glucose sensor immediately after the time period; and
determining an occurrence of a post-implantation loss of sensitivity event if the signal value is greater than a predetermined value.
4. The method of claim 1 , wherein identifying the post-implantation loss of sensitivity further comprises determining a pH of a biological fluid surrounding the continuous glucose sensor.
5. The method of claim 1 , wherein identifying the post-implantation loss of sensitivity further comprises:
measuring a concentration value of a non-glucose analyte; and
determining an occurrence of a post-implantation loss of sensitivity event if the concentration value of the non-glucose analyte changes more than a predetermined amount.
6. The method of claim 1 , wherein the continuous glucose sensor comprises a first electrode and a second electrode.
7. The method of claim 6 , wherein the first electrode and second electrode have different dimensions.
8. The method of claim 7 , wherein the second electrode is configured to have a dimension that positions the second electrode post-implantation outside of a site affected by cessation or reduction of blood flow.
9. The method of claim 6 , wherein at least one of the first electrode and the second electrode is configured to minimize tissue trauma from implantation.
10. The method of claim 6 , further comprising:
determining that the second electrode is positioned outside of a site affected by cessation or reduction of blood flow; and
wherein processing the sensor data responsive to the identification of the loss of sensitivity comprises according more weight to sensor data generated by the second electrode than sensor data generated by the first electrode.
11. The method of claim 1 , wherein the post-implantation loss of sensitivity of the continuous glucose sensor is due to accumulation of biological material on a membrane of the continuous glucose sensor.
12. The method of claim 1 , wherein the post-implantation loss of sensitivity of the continuous glucose sensor is due to a biological encapsulation of at least a portion of the continuous glucose sensor.
13. The method of claim 1 , wherein the post-implantation loss of sensitivity is transient.
14. The method of claim 1 , wherein the post-implantation loss of sensitivity of the continuous glucose sensor is due to a local cessation of blood flow in an implantation area.